A Phase III Study of SHR-A2102 Versus Investigator-selected Therapy in Advanced Urothelial Carcinoma

Clinical trial NCT06738251 · RECRUITING

Trial details

NCT number: NCT06738251
Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Advanced Urothelial Carcinoma

Start date: 2025-02-12
Primary completion: 2026-07-01
Enrollment: 402

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.